Last reviewed · How we verify
Rifabutin, Clarithromycin, and Clofazimine
Rifabutin, Clarithromycin, and Clofazimine, marketed by Medstar Health Research Institute, is a combination therapy with a key composition patent expiring in 2028. The primary strength of this drug lies in its established market presence and the protection offered by its key patent. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Rifabutin, Clarithromycin, and Clofazimine |
|---|---|
| Sponsor | Medstar Health Research Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (PHASE2, PHASE3)
- RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease (PHASE3)
- The Individualized M(X) Drug-resistant TB Treatment Strategy Study (PHASE4)
- Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) Plus AIDS (PHASE3)
- A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS (PHASE2)
- Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease (PHASE3)
- Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: